Drug Trial Radar · NCT01651871
Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Apr 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
779
Actual
Start
Jul 2012
Primary completion
Nov 2012
Study completion May 2013
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to examine the efficacy and safety of S-555739/cetirizine HCl compared with the individual components and placebo.
Conditions
- Seasonal Allergic Rhinitis
Interventions
S-555739 Dose 1Drug
S-555739 Dose 2Drug
Cetirizine HCl Dose 1Drug
S-555739 placeboDrug
Cetirizine HCl placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in average morning/evening (AM/PM) reflective Total Nasal Symptom Score (rTNSS)Time frame: Change from baseline through the 2-week treatment period (Day 2 through Day 15)
- Incidence of adverse events (AEs)Time frame: From Screening period to Week 6 (Follow-up)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.